Compare Cassava Sciences Inc (FLNA) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lumen Technologies Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Lumen Technologies Inc trades at $6.32 (market cap $6.56B). The key difference: Lumen Technologies Inc is far larger — about 123.4× Cassava Sciences Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | LUMN | |
|---|---|---|
Market Cap | $53.14M | $6.56B |
Sector | Health | Media |
52-Week High | $4.64 | $11.83 |
52-Week Low | $1.09 | $3.70 |
Enterprise Value | -$33.43M | $18.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
LUMN trades at $6.37, showing no change recently, with a bearish technical signal and mixed earnings history. The company reported a net loss of $1.74B in 2025, though revenue remains substantial at $12.40B. Recent developments include the acquisition of Alkira to enhance AI networking capabilities and cost-cutting initiatives targeting $1B in savings by 2027. Analyst consensus is cautious, with a hold-heavy rating distribution and a $8.25 price target.
The outlook is challenging due to persistent losses and high debt, but strategic acquisitions and efficiency efforts offer potential upside. Risks include execution hurdles and competitive pressures in telecom. Investors should weigh the low P/S ratio against profitability concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
